Vasomedical data shows effectiveness of EECP therapy in heart failure

By Lisa Kerner

Charlotte, N.C., Sept. 19 - Vasomedical, Inc. made three presentations highlighting the benefits of its EECP (external counterpulsation) therapy in patients with heart failure at the 10th Annual Heart Failure Society of America Scientific Meeting in Seattle.

EECP therapy is typically given in a doctor's office or outpatient clinic in 35 one-hour sessions over 4 to 7 weeks using synchronized inflated cuffs.

Data demonstrated that heart failure patients were able to double their exercise capacity following a course of EECP therapy and maintain the benefit at one-year follow-up, with improvements in quality of life.

A second set of data from a cohort of 53 adult patients with systolic heart failure showed significant improvements in symptom status, exercise capacity, quality of life and ventricular function.

Data from the International EECP Patient Registry showed that EECP therapy is equally effective in diabetic and non-diabetic patients suffering from angina and heart failure.

Vasomedical, based in Westbury, N.Y., specializes in EECP external counterpulsation systems.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.